Human epithelial-type ovarian tumour marker beta-2-microglobulin is regulated by the TGF-β signaling pathway

[1]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[2]  Jing-he Li,et al.  ATP5b and β2-microglobulin are predictive markers for the prognosis of patients with gallbladder cancer , 2015, Journal of Molecular Histology.

[3]  Xuezhong Chen,et al.  Characterization of β2-microglobulin expression in different types of breast cancer , 2014, BMC Cancer.

[4]  P. Terasaki,et al.  Gastric cancer progression may involve a shift in HLA‐E profile from an intact heterodimer to β2‐microglobulin‐free monomer , 2014, International journal of cancer.

[5]  M. Kaur,et al.  β2-Microglobulin-mediated Signaling as a Target for Cancer Therapy , 2014, Anti-cancer agents in medicinal chemistry.

[6]  Guoxiong Xu,et al.  Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway , 2014, International journal of oncology.

[7]  Michael J. Pokrass,et al.  Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy. , 2013, Molecular immunology.

[8]  Jinsong Liu,et al.  TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. , 2013, Cancer research.

[9]  P. Leung,et al.  TGF-Beta Induces Serous Borderline Ovarian Tumor Cell Invasion by Activating EMT but Triggers Apoptosis in Low-Grade Serous Ovarian Carcinoma Cells , 2012, PloS one.

[10]  C. Volteau,et al.  HLA‐E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression , 2012, International journal of cancer.

[11]  Jae Hoon Kim,et al.  Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma , 2012, Journal of Molecular Medicine.

[12]  S. Paydaş,et al.  Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia , 2012, Medical Oncology.

[13]  P. Hoffmann,et al.  Transforming growth factor‐beta‐induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells , 2011, International journal of cancer.

[14]  L. Chung,et al.  β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. , 2011, Cancer research.

[15]  Lilya V. Matyunina,et al.  Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells , 2009, BMC Medical Genomics.

[16]  Y. Li,et al.  Identification of beta2-microglobulin as a potential target for ovarian cancer , 2009, Cancer biology & therapy.

[17]  Joel H. Saltz,et al.  BMC Systems Biology , 2022 .

[18]  A. Graham,et al.  β2microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients , 2008, British Journal of Cancer.

[19]  M. Gross,et al.  β-2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer , 2007, Clinical Cancer Research.

[20]  P. Leung,et al.  Role of endocrine and growth factors on the ovarian surface epithelium , 2007, The journal of obstetrics and gynaecology research.

[21]  F. Marshall,et al.  β2-Microglobulin Promotes the Growth of Human Renal Cell Carcinoma through the Activation of the Protein Kinase A, Cyclic AMP–Responsive Element-Binding Protein, and Vascular Endothelial Growth Factor Axis , 2006, Clinical Cancer Research.

[22]  F. Bouet,et al.  Constitutive expression of TGF-bêta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. , 2003, European cytokine network.

[23]  K. Miyazono,et al.  Two major Smad pathways in TGF‐β superfamily signalling , 2002, Genes to cells : devoted to molecular & cellular mechanisms.

[24]  J. Graff,et al.  Transforming Growth Factor-β Receptor Type I Gene Is Frequently Mutated in Ovarian Carcinomas , 2001 .

[25]  N. Wake,et al.  Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. , 2000, Cancer research.

[26]  H. Lodish,et al.  Role of transforming growth factor beta in human disease. , 2000, The New England journal of medicine.

[27]  J. Massagué,et al.  Transcriptional control by the TGF‐β/Smad signaling system , 2000 .

[28]  T. Enomoto,et al.  Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. , 1998, Cancer research.

[29]  E. Yap,et al.  Molecular genetic analysis of TGF-beta1 in ovarian neoplasia. , 1997, Journal of experimental & clinical cancer research : CR.

[30]  M. Gerdes,et al.  β-2 Microglobulin Is Mitogenic to PC-3 Prostatic Carcinoma Cells and Antagonistic to Transforming Growth Factor β1 Action , 1995 .

[31]  A. Nyska,et al.  Elevated pretreatment levels of soluble CD8 and Beta-2-microglobulin as indicators of relapse in breast-cancer patients. , 1994, International Journal of Oncology.

[32]  R. Bast,et al.  Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. , 1992, American journal of obstetrics and gynecology.

[33]  A. R. Aroor,et al.  Evaluation of serum β2-microglobulin in oral cancer , 1992 .

[34]  I. Ginjaar,et al.  The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. , 1987, Journal of immunology.

[35]  B. Malissen,et al.  An antigenic determinant of human beta 2-microglobulin masked by the association with HLA heavy chains at the cell surface: analysis using monoclonal antibodies. , 1981, Journal of immunology.

[36]  N. Javadpour,et al.  Serum β2 microglobulin levels in patients with testicular cancer , 1980 .

[37]  E. Mackay,et al.  Carcinoembryonic Antigen and β2‐Microglobulin as Serum Tumor Markers in Women with Genital Cancer , 1979, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[38]  S. Aamdal,et al.  Immune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma , 2014, International journal of cancer.

[39]  S. J. Adair,et al.  Immunological profiling of a panel of human ovarian cancer cell lines , 2007, Cancer Immunology, Immunotherapy.

[40]  M. Gross,et al.  Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  N. Agnantis,et al.  Serum estimation of carcinoembryonic antigen, beta(2)-microglobulin and calcitonin as tumor markers in primary lung cancer. , 2003, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[42]  M. Gerdes,et al.  Beta-2 microglobulin is mitogenic to PC-3 prostatic carcinoma cells and antagonistic to transforming growth factor beta 1 action. , 1995, Cancer research.

[43]  A. R. Aroor,et al.  Evaluation of serum beta 2-microglobulin in oral cancer. , 1992, Australian dental journal.

[44]  G. Karvountzis,et al.  Serum beta 2 microglobulin in malignant lymphoproliferative disorders. , 1985, Cancer.

[45]  N. Javadpour,et al.  Serum beta 2 microglobulin levels in patients with testicular cancer. , 1980, Urology.